DE69619979D1 - Feste zusammensetzungen mit einem nicht-amorphem wirkstoff und polyäthylenoxyd - Google Patents

Feste zusammensetzungen mit einem nicht-amorphem wirkstoff und polyäthylenoxyd

Info

Publication number
DE69619979D1
DE69619979D1 DE69619979T DE69619979T DE69619979D1 DE 69619979 D1 DE69619979 D1 DE 69619979D1 DE 69619979 T DE69619979 T DE 69619979T DE 69619979 T DE69619979 T DE 69619979T DE 69619979 D1 DE69619979 D1 DE 69619979D1
Authority
DE
Germany
Prior art keywords
active substance
polyethylene oxide
solid compositions
amorphous active
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE69619979T
Other languages
English (en)
Other versions
DE69619979T2 (de
Inventor
Pawan Seth
Andre Stamm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharma Pass SA
Original Assignee
Pharma Pass SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9478138&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69619979(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharma Pass SA filed Critical Pharma Pass SA
Application granted granted Critical
Publication of DE69619979D1 publication Critical patent/DE69619979D1/de
Publication of DE69619979T2 publication Critical patent/DE69619979T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
DE69619979T 1995-04-14 1996-04-15 Feste zusammensetzungen mit einem nicht-amorphem wirkstoff und polyäthylenoxyd Revoked DE69619979T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9504520 1995-04-14
PCT/FR1996/000574 WO1996032097A1 (fr) 1995-04-14 1996-04-15 Compositions solides contenant du polyethyleneoxyde et un principe actif non amorphe

Publications (2)

Publication Number Publication Date
DE69619979D1 true DE69619979D1 (de) 2002-04-25
DE69619979T2 DE69619979T2 (de) 2002-11-21

Family

ID=9478138

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69619979T Revoked DE69619979T2 (de) 1995-04-14 1996-04-15 Feste zusammensetzungen mit einem nicht-amorphem wirkstoff und polyäthylenoxyd

Country Status (6)

Country Link
EP (1) EP0830129B1 (de)
AT (1) ATE214596T1 (de)
AU (1) AU5652796A (de)
CA (1) CA2218054C (de)
DE (1) DE69619979T2 (de)
WO (1) WO1996032097A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
CN1211928A (zh) * 1996-11-04 1999-03-24 联合碳化化学品及塑料技术公司 提高基本不溶于水的化合物溶解度的方法
KR100545480B1 (ko) * 1997-06-06 2006-01-24 데포메드 인코퍼레이티드 매우 가용성인 약물의 제어방출을 위한 위체류성 경구약물제형
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
DE69831335T3 (de) 1997-06-06 2015-01-15 Depomed, Inc. Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung
EP0974343B1 (de) * 1998-07-22 2004-09-29 Pharma Pass II LLC Verfahren zur Herstellung einer festen Zubereitung enthaltend Metoprolol
EP0987020A1 (de) * 1998-09-04 2000-03-22 Pharma Pass LLC Zusammensetzung enthaltend Metoprolol und Verfahren zur Herstellung
HUP9902351A3 (en) * 1998-07-22 2001-01-29 Pharma Pass L L C Irvine Solid compositions containing metoprolol and process for producing the same
HU229295B1 (en) * 1999-08-04 2013-10-28 Astellas Pharma Inc Stable medicinal compositions for oral use
NZ527930A (en) * 2001-03-16 2005-11-25 Andrx Pharmaceuticals Llc Controlled release sulfonylurea formulation
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
AU2003240213A1 (en) * 2002-06-24 2004-01-06 Ranbaxy Laboratories Limited Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US7442387B2 (en) * 2003-03-06 2008-10-28 Astellas Pharma Inc. Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US8071119B2 (en) 2007-05-14 2011-12-06 Sustained Nano Systems Llc Controlled release implantable dispensing device and method
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
EP3003297A4 (de) 2013-06-05 2017-04-19 Synchroneuron Inc. Acamprosat-formulierungen, verfahren zur verwendung davon und kombinationen damit

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4764378A (en) * 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
US5273758A (en) * 1991-03-18 1993-12-28 Sandoz Ltd. Directly compressible polyethylene oxide vehicle for preparing therapeutic dosage forms

Also Published As

Publication number Publication date
EP0830129B1 (de) 2002-03-20
WO1996032097A1 (fr) 1996-10-17
DE69619979T2 (de) 2002-11-21
EP0830129A1 (de) 1998-03-25
CA2218054C (en) 2005-10-18
AU5652796A (en) 1996-10-30
CA2218054A1 (en) 1996-10-17
ATE214596T1 (de) 2002-04-15

Similar Documents

Publication Publication Date Title
DE69619979T2 (de) Feste zusammensetzungen mit einem nicht-amorphem wirkstoff und polyäthylenoxyd
SE8300736D0 (sv) Novel pharmacologically active compounds
FI973828A0 (fi) Yhdisteitä ja koostumuksia aktiivisten aineiden annostelemiseksi
EE03177B1 (et) Heterobitsüklilised ühendid, nende saamismeetod ja nimetatud ühendeid sisaldavad farmatseutilised kompositsioonid
ES2074846T3 (es) Nuevas naftil-etil-ureas y naftil-etil-tioureas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen.
NO971889D0 (no) Forbindelser og sammensetninger for levering av aktive midler
FI934274A (fi) N-sulfonyl-2-oxi-indolderivat, deras framstaellning och dessa innehaollande farmaceutiska kompositioner
NO971568D0 (no) Analoger av keratinocyttvekstfaktor
KR890700125A (ko) 신규 벤즈이미다졸 유도체, 그 제조방법 및 이 화합물을 함유하는 제약 조성물
ES8707732A1 (es) Procedimiento para preparar 1,2,4 triazolo 1,5-c quinazolinas
EA200000181A1 (ru) Фармацевтические композиции, содержащие витамин d и кальций, их приготовление и терапевтическое применение
SE8404065D0 (sv) Novel biologically active compounds
HUT38097A (en) Process for preparing substituted benzopyrans and pharmaceutical compositions containing them as active substances
IT1298338B1 (it) Composizioni farmaceutiche per l'ulcera
RU94038042A (ru) Производные гексагидроазепинов, фармацевтическая композиция на их основе и антипсихотропный агент
CA2077991A1 (en) Cosmetics and pharmaceuticals containing extensins and related methods
DE69613395T2 (de) Schwefelenthaltende di-ter-butylphenol-verbindungen brauchbar als entzündungshemmende mittel
IL104485A0 (en) Benzimidazoles,their preparation and pharmaceutical compositions containing them
SE9403389D0 (sv) Pharmaceutical composition containing derivattves of sex hormones
MD970269A (en) Clavulanates
DE3681127D1 (de) Primycin enthaltendes kolloidales grundgel, verfahren zu dessen herstellung, dieses grundgel enthaltende pharmazeutische und pharmako-kosmetische kompositionen.
EA199700223A1 (ru) Бициклические антагонисты тахикининов, их получение и применение в фармацевтической композиции
ATE120369T1 (de) Verwendung stabiler oxapenem-3-carbonsäuren zur herstellung beta-lactamase hemmender arzneimittel.
NZ220800A (en) Tetrahydrobenzothiazoles and pharmaceutical compositions
SE8503447D0 (sv) Farmaceutiska och kosmetiska kompositioner, innehallande dihydroxi-1,8-fenyl-10-antron-9 som verksam bestandsdel, samt sett att framstella den verksamma foreningen

Legal Events

Date Code Title Description
8363 Opposition against the patent
8331 Complete revocation